Newsroom

The EITRE system will be used in Professor Stella Pang’s research work at the Department of Electronic Engineering at City University of Hong Kong. Professor Pang, who previously worked as Professor at University of Michigan in the US, is a user of Obducat’s NIL technology since 2003. The EITRE system will be used for research work within the area of 3D scaffolds and tissue engineering. NIL is the only nanopatterning technology that allows repeated and fully controlled 3-D surfaces to be produced at the nanoscale. These 3D nanodevices...

Current knowledge in modern material science allows for the preparation of a myriad of tailored nanomaterial and self-assembly technologies are the most used methods for preparation of nanostructures. This progress has created a huge and growing interest for high-resolution patterning of films to create the next generation of materials with improved performance and functionality. The aim of the GREENANOFILM project is to design and develop, using environmentally friendly processes, ultra-high resolution patterned nano-organized films using self-assembly...

The contract includes agreement regarding supply of a Sindre® 400 NIL-system, capable of imprinting substrate sizes of up to 4-inch, guarantee of supply of consumables - based on Obducat’s patented IPS® and STU® technology – that are used in the manufacturing process and supply of service and support, which includes regular maintenance visits as well as short response time for service issues. Delivery of the Sindre® 400 NIL-system is scheduled to take place in Q3 2014, at which time Obducat will expand its local organization...

Obducat and Kimberly-Clark entered into a Joint Development Agreement in June 2011. In May 2013 Kimberly-Clark placed a purchase order for a Sindre NIL pilot manufacturing line with Obducat. In November 2013 a Factory Acceptance Test was concluded at Obducat facilities and now the Site Acceptance Test, performed at Kimberly-Clark facilities in the US, has been approved. The pilot line will be used for production of medical devices being developed by Kimberly-Clark. The FDA approval process is ongoing and provided that the approval can be obtained...

Progresses in nano patterning technology has enabled improvement in performance and quality of existing products as well as the introduction of new products on the market. This progress however is still restricted by limitations in the size of surfaces that can be nano patterned. In order to enable the utilization of these nano-enabled benefits in industries where manufacturing is based on patterning large surfaces as well, Obducat initiated the formation of this consortium which will address the development of large area NIL equipment, stampers...

Biosensor and microfluidic technologies are a key topic for the development of new Point-of-Care (POC) analysis system useful in the health care sector. In order to further broaden the use of these POC systems a new generation of bio analytical tools must be developed which will improve characteristics in terms of stability, sensitivity, selectivity at the same time as the manufacturing cost can be reduced. In the field of electrochemical biosensors, the development of new electrode surfaces and recognition elements with high stability, sensitivity...

Obducat and Kimberly-Clark entered into a Joint Development Agreement in June 2011. Based on the successful joint development efforts the parties have signed a Purchase Agreement concerning a NIL (Nano Imprint Lithography) pilot manufacturing line. The pilot line will be used for production of a medical device being developed by Kimberly-Clark. The pilot line is a "first-of-its-kind" and is scheduled to be delivered during fourth quarter this year. This is information that Obducat AB (publ) is required to disclose pursuant to the Swedish...

The target of the collaboration is to create a pilot scale NIL (Nano Imprint Lithography) solution to produce unique Kimberly-Clark devices. The application will remain undisclosed for the time being. A ramp into volume production is targeted provided that the development activities reach agreed performance criteria. This is information that Obducat AB is required to make in compliance with the Swedish Securities Market Act. The information was submitted for publication on June 28, 2011 at 08:50 CET. For further information, please contact: Patrik...

This is information that Obducat AB is required to make in compliance with the Swedish Securities Market Act. The information was submitted for publication on April 29, 2011 at 07:30 CET. For further information, please contact: Patrik Lundström, CEO, Obducat AB, +46 40-36 21 00 or 703 - 27 37 38 Henri Bergstrand, Chairman of the Board, Obducat AB, +46 40-36 21 00 or 708 - 88 72 45 About Obducat AB Obducat AB is an innovative developer and supplier of technologies, products and processes used for the production and replication of advanced micro...